Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05311397 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.
MinorTrial completedPrimary completion date changed from estimate of Jun 30, 2026 to Apr 9, 2026 · Enrollment target: estimated 120 to confirmed 129 · Start date: Aug 9, 2018 to Aug 1, 2018 · 1 moreShow 4 more changesShow less
Primary completion date changed from estimate of Jun 30, 2026 to Apr 9, 2026
Enrollment target: estimated 120 to confirmed 129
Start date: Aug 9, 2018 to Aug 1, 2018
Eligibility criteria expanded, about 9 words
MinorRe-verified, no change to tracked fieldsv5
NotablePrimary completion date: Jun 30, 2025 to Jun 30, 2026Trial status: Recruiting to Active, Not Recruiting · Completion date: Dec 31, 2025 to Dec 31, 2026 · Site details revisedv4Show 3 more changesShow less
Trial status: Recruiting to Active, Not Recruiting
Completion date: Dec 31, 2025 to Dec 31, 2026
Site details revised
NotableLead sponsor: Sichuan Kelun Pharmaceutical Research Institute Co., Ltd. to Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.Primary completion date: Jun 30, 2023 to Jun 30, 2025 · Completion date: Dec 31, 2023 to Dec 31, 2025v3Show 2 more changesShow less
Primary completion date: Jun 30, 2023 to Jun 30, 2025
Completion date: Dec 31, 2023 to Dec 31, 2025
MinorSecondary endpoints: details revised at 1 of 3 entriesv2
MinorStudy First Submitted
Stopped: an ongoing trial was terminated, suspended or withdrawn.
Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This is a single arm, open-label, dose-escalation and dose-expansion phase I study evaluating A166 in patients with HER2-expressing locally advanced or metastatic solid tumors.